Treatment of Obstructive Sleep Apnea in Chronic Kidney Disease

Not Applicable

Completed

• Conditions: Sleep Apnea, Obstructive; Renal Insufficiency, Chronic
• Interventions: Other: No CPAP; Device: CPAP

• Registration Number: NCT02420184
• Lead Sponsor: University of Calgary

Brief Summary

This study is being conducted to determine whether treatment of obstructive sleep apnea (OSA) in patients with chronic kidney disease (CKD) improves kidney function. Half of the participants will receive continuous positive airway pressure (CPAP) treatment for their OSA in addition to their regular CKD treatment, while the other half will only receive their regular CKD treatment.

Detailed Description

Obstructive sleep apnea (OSA) and associated hypoxemia during sleep have been associated with a decline in kidney function. The abnormalities in kidney function associated with OSA have been improved by treatment of OSA with continuous positive airway pressure (CPAP), which is a common and effective therapy for OSA. Up to now, clinical research on the impact of OSA on kidney function has been performed on patients without CKD. This study will examine the impact of CPAP therapy on kidney function in patients with CKD.

CKD patients with OSA and nocturnal hypoxemia will be randomized into one of two groups where half will receive treatment of their OSA with CPAP and the other half will not. All participants will have kidney function monitored every 3 months for a year by measurement of serum creatinine and proteinuria. The change in estimated glomerular filtration rate (eGFR) and proteinuria between the two groups will be assessed to determine whether treatment of OSA improves kidney function in patients with CKD.

Study Timeline

• Study First Submitted: 2015-04-14
• Study First Submitted QC: 2015-04-16
• Study First Posted: 2015-04-17
• Study Start: 2015-06
• Primary Completion: 2021-12
• Study Completion: 2021-12
• Status Verified: 2022-05
• Last Update Submitted: 2022-05-19
• Last Update Posted: 2022-05-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 57

Inclusion Criteria

• CKD stage 3 or 4
• OSA (RDI>5) and nocturnal hypoxemia (SaO2 <90% for >12% of night)

Exclusion Criteria

• Failure to meet inclusion criteria
• Current therapy with CPAP or supplemental oxygen
• Severe daytime sleepiness reflected by an Epworth Sleepiness Score >15
• Any driver who holds a commercial drivers' license or who reports a recent history (past 6 months) of a road traffic accident
• Severe nocturnal hypoxemia reflected by mean SaO2 <80% during level 3 sleep testing
• Daytime hypoxemia reflected by partial pressure of oxygen in arterial blood (PaO2) less than 60 millimetres of mercury (mmHg) during wakefulness
• Hypoventilation reflected by partial pressure of carbon dioxide in arterial blood (PaCO2) greater than 45 millimetres of mercury (mmHg) during wakefulness
• Central sleep apnea that accounts for >50% of the estimated RDI
• Unable to provide informed consent

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
No CPAP	No CPAP	Participants will receive standard medical care for CKD.
CPAP Therapy	CPAP	Participants will receive standard medical care for CKD as well as CPAP therapy for the duration of the study (1 year).

Primary Outcome Measures

Name	Time	Method
eGFR (estimated glomerular filtration rate)	12 months	Change in eGFR in CPAP group compared to control group.

Secondary Outcome Measures

Name	Time	Method
Pittsburgh Sleep Quality Index (PSQI)	12 months	The PSQI is a validated, self-reported questionnaire that measures subjective sleep quality by asking patients about difficulties initiating and maintaining sleep. The change in PSQI in CPAP group will be compared to control.
Epworth Sleepiness Scale (ESS)	12 months	The ESS is a self-reported questionnaire that measures subjective sleepiness. Patients are asked to rate the tendency to fall asleep in eight passive situations. The change in ESS in the CPAP group will be compared to control
ACR (albumin/creatinine ratio)	12 months	Change in albumin/creatinine ratio (ACR) in CPAP group compared to control group.
Kidney Disease Quality of Life questionnaire (KDQoL)	12 months	The KDQoL focuses on the health concerns of patients with chronic kidney disease26. This has been modified slightly, by omitting 2 questions that ask about dialysis, to make it suitable for the non-dialysis CKD population. The change in KDQoL in the CPAP group will be compared to control.